News

Date Title View
Toggle Summary Aerie Pharmaceuticals Announces Positive Phase 2a Clinical Results for its Novel, Dual Mechanism Compound, AR-13324, for the Treatment of Glaucoma View HTML
Toggle Summary Aerie Pharmaceuticals Announces Positive Phase 2a Clinical Results for a Fixed Combination of its Rho Kinase Inhibitor, AR-12286, with Travoprost for the Treatment of Glaucoma View HTML
Toggle Summary Aerie Pharmaceuticals Appoints Richard J. Rubino as Chief Financial Officer View HTML
Toggle Summary American Journal of Ophthalmology - Ocular Hypotensive Effect of the Rho Kinase Inhibitor AR-12286 in Patients With Glaucoma and Ocular Hypertension View HTML
Toggle Summary Aerie Pharmaceuticals Completes $30 Million Series B Financing to Fund Further Development of Innovative Glaucoma Product Portfolio
Financing Underscores Strong Clinical Progress and Positive Data in Lead Program
View HTML
Toggle Summary Biocentury - RhoKing Glaucoma View HTML
Toggle Summary Aerie Pharmaceuticals’ ROCK Inhibitor, AR-12286, Demonstrates Positive Results in Glaucoma Patients in a Phase 2a Study
Novel Drug has Potential to Create Significant Improvement in Function of Diseased Tissue
View HTML